Navigation Links
c-Met may be a biomarker for metastatic hepatocellular carcinoma
Date:9/28/2010

DENVER Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

HCC is the most common primary malignant tumor of the liver; c-Met is a receptor for hepatocyte growth factor that appears to drive liver cancer growth, invasion and metastasis.

"Current therapies for HCC patients are 'one size fits all.' We propose that molecular profiling will enable better therapy for HCC patients with a c-Met positive tumor," said Hanning You, M.D., Ph.D., postdoctoral fellow working in the laboratory of C. Bart Rountree, M.D., in the departments of pediatrics and pharmacology, at the Pennsylvania State University College of Medicine, Hershey, Pa.

Using a preclinical translational study to validate c-Met as a target for HCC, You and colleagues found c-Met was highly overexpressed in metastatic liver cancer cells.

"By targeting c-Met we were able to suppress tumor growth in vivo and kill these metastatic liver cancer cells," said You.

Since c-Met inhibitor stopped proliferation and tumor growth of metastatic HCC cells, the researchers concluded that c-Met might be a potential personalized target of metastatic HCC. In addition, they found that results of a separate meta-analysis of six studies and 1,051 patients showed that c-Met activation is associated with poor prognosis in HCC.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
2. Personalizing cancer: Creating biomarkers from tumor DNA
3. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
4. Reliable biomarkers needed for early detection of liver cancer
5. More Reliable Biomarkers Needed for Early Detection of Liver Cancer
6. UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis
7. BATTLE links potential biomarkers to drugs for lung cancer
8. UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis
9. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
10. A prognostic and predictive biomarker for nonsmall cell lung cancer
11. Hydrophobic proteins: Potential biomarkers for colorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Ongoing news ... Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer look ... released today illustrates the prevalence and causes of TBI among the aging population, and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Gout is ... and brings pain that is often severe, with intense swelling and redness. It is ... eight million people, but older adults are the most susceptible, according to the February ...
(Date:2/10/2016)... ... ... AHRA: The Association for Medical Imaging Management announced today ... as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead with ... with their own organizational staff and leadership. , “I am so excited ...
(Date:2/10/2016)... ... 10, 2016 , ... A national ergonomics pioneer , ... event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the expo ... longest running and largest worker's compensation event in Ohio, organizers of the safety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader in ... its Series D investment round on February 5, 2016. ... Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical manufacturer, ... Partners, SCP Vitalife Partners, Generali Financial Holdings and both ...
(Date:2/10/2016)... , Feb. 10, 2016 Intouch ... recently identified an industry-wide trend regarding the evolution ... allows organizations to efficiently deliver compelling sales presentations ... 2011 and another in 2015, Intouch uncovered that ... tablet devices and DSAs, many are not using ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
Breaking Medicine Technology: